Pharmaceuticals - Community Register

  

Community list of not active orphan medicinal products


WITHDRAWN  

Product information

Linsitinib

EU orphan designation number: EU/3/12/977
Active ingredient: Linsitinib
Indication: Treatment of adrenal cortical carcinoma
Sponsor: Astellas Pharma Europe B.V.
Sylviusweg 62, NL-2333 BE Leiden, Nederland

   Public summary of scientific opinion    

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
04/04/2012 Centralised Orphan - Designation EMA/OD/145/11 (2012)2347 of 02/04/2012
05/02/2013 Other procedure
08/02/2013 Centralised Orphan - Removal of orphan designation from Community Register